Floatz logo

68 assets in Lung Carcinoma

Therapeutic assets addressing Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
Lung Carcinoma
Taiho Oncology, Inc.P3BB (66)
OTL-38
Lung Carcinoma
On Target Laboratories, LLCP4BB (65)
Etoposide
Lung Carcinoma
SystImmune Inc.P3BB (64)
Carboplatin
Lung Carcinoma
SystImmune Inc.P3B (63)
Nivolumab
Lung Carcinoma
M.D. Anderson Cancer CenterP2B (63)
Pembrolizumab
Lung Carcinoma
Essen BiotechP2B (62)
Atezolizumab
Lung Carcinoma
SystImmune Inc.P3B (60)
Bl-M14D1
Lung Carcinoma
SystImmune Inc.P3B (60)
Durvalumab
Lung Carcinoma
University of British ColumbiaP2B (60)
Lurbinectedin
Lung Carcinoma
SystImmune Inc.P3B (60)
Zipalertinib
Lung Carcinoma
Taiho Oncology, Inc.P3B (60)
Binimetinib
Lung Carcinoma
University of California, San FranciscoP2B (58)
Capivasertib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Crizotinib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Dabrafenib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Dasatinib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Defactinib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Esomeprazole
Lung Carcinoma
Rush University Medical CenterP2CCC (53)
Famitinib
Lung Carcinoma
Shanghai Cancer Hospital, ChinaP2CCC (53)
Fexagratinib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Gadopiclenol
Lung Carcinoma
University of ZurichP2CCC (53)
Gsk-2636771
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipatasertib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Larotrectinib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Lazertinib
Lung Carcinoma
Samsung Medical CenterP2CCC (53)
Metformin
Lung Carcinoma
Northwestern UniversityP2CCC (53)
Olanzapine
Lung Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Osimertinib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Palbociclib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pertuzumab
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Relatlimab
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Sapanisertib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Serplulimab
Lung Carcinoma
Xi JunjieP2CCC (53)
Sotorasib
Lung Carcinoma
Vestre Viken Hospital TrustP2CCC (53)
Trametinib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Trastuzumab
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Trastuzumab Emtansine
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ulixertinib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Vismodegib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Vorolanib
Lung Carcinoma
Li-kun ChenP2CCC (53)
Yttrium-90-Labeled Fibroblast Activation Protein Inhibitor
Lung Carcinoma
Prof. Dr. Cemil Tascıoglu Education and Research Hospital OrganizationP2CCC (53)
Adavosertib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (52)
Taselisib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Copanlisib
Lung Carcinoma
National Cancer Institute (NCI)P2CCC (49)
Ebnk-001
Lung Carcinoma
Essen BiotechP1/2CCC (48)
Interleukin-15
Lung Carcinoma
Essen BiotechP1/2CCC (48)
SLC391
Lung Carcinoma
SignalChem Lifesciences CorporationP1/2CC (47)
Fludeoxyglucose
Lung Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (46)
Silevertinib
Lung Carcinoma
Black Diamond Therapeutics, Inc.P1/2CC (45)
Showing 1 to 50 of 68 assets
PreviousPage 1 of 2Next